• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Anti-VEGF Therapy for Diabetic Retinopathy Gets to the Root Cause


Drugs block the formation of tiny blood vessels in the retina that are prone to breaking open, resulting in bleeds that can cause serious vision impairment and blindness, explains ADA chief scientific and medical officer, Robert Gabbay, in this conclusion of a four-part video series.

When the leaky blood vessels of diabetic retinopathy occur, they compensate by sending out growth factors that spur on the growth of new blood vessels.

The trouble is that those new blood vessels are poorly formed and prone to breaking open and causing a bleed that can threaten a person’s vision.

Related: ADA's Dr. Robert Gabbay Discusses Patient, System Challenges to Eyecare

Drug treatment that block those growth factors, which are called vascular endothelial growth factors (VEGF), can interrupt this process and reduce the risk of vision impairment and loss from diabetic retinopathy.

“It really gets to the pathophysiology of the disease — preventing the development of the new blood vessels,” explained Robert Gabbay, the chief scientific and medical officer for the American Diabetes Association in a recent interview with Managed Healthcare Executive. ®

The association, VSP Vision Care, and Regeneron, have launched a public health campaign to encourage people with diabetes to get annual eye exams. Regeneron markets an anti-VEGF drug called Eyelea (aflibercept).

Gabbay said another way to treat the diabetic retinopathy is to cauterize blood vessels by burning tiny holds in the retina. Gabbay said this is the “tried and true” approach but used after anti-VEGF therapy.

“Ideally, we catch things early enough to be able to use anti-VEGF therapy,” said Gabbay.

Related Videos
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 8 - "Demographic Differences That Impact Care"
Video 7 - "Gaps in Diabetes Education and Self Efficacy"
Video 6 - "Key Takeaways and Unmet Needs in Diabetes Treatment"
Video 5 - "Allocation of Investment and Value-Based Arrangements in Diabetes Care "
Video 3 - "Integrating CGMs into Diabetes Treatment Programs"
Video 2 - "Identifying Inequities in CGM Access"
Video 1 - "Challenges in Treating High-Risk Patients With Diabetes"
Related Content
© 2024 MJH Life Sciences

All rights reserved.